147 related articles for article (PubMed ID: 36126967)
1. Comparison of pharmacokinetics software for therapeutic drug monitoring of piperacillin in patients with severe infections.
Rodríguez-Báez AS; Jiménez-Meseguer M; Milán-Segovia RDC; Romano-Moreno S; Barcia E; Ortiz-Álvarez A; García-Díaz B; Medellín-Garibay SE
Eur J Hosp Pharm; 2024 Apr; 31(3):201-206. PubMed ID: 36126967
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
3. Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
Paal M; Heilmann M; Koch S; Bertsch T; Steinmann J; Höhl R; Liebchen U; Schuster C; Kleine FM; Vogeser M
Clin Lab; 2019 Sep; 65(9):. PubMed ID: 31532096
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
Bauer SR; Salem C; Connor MJ; Groszek J; Taylor ME; Wei P; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
[TBL] [Abstract][Full Text] [Related]
5. Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.
Greppmair S; Brinkmann A; Roehr A; Frey O; Hagel S; Dorn C; Marsot A; El-Haffaf I; Zoller M; Saller T; Zander J; Schatz LM; Scharf C; Briegel J; Minichmayr IK; Wicha SG; Liebchen U
Intensive Care Med; 2023 Aug; 49(8):966-976. PubMed ID: 37439872
[TBL] [Abstract][Full Text] [Related]
6. Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.
Rachow T; Schlüter V; Bremer-Streck S; Lindig U; Scholl S; Schlattmann P; Kiehntopf M; Hochhaus A; von Lilienfeld-Toal M
Infection; 2017 Oct; 45(5):629-636. PubMed ID: 28516432
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
[TBL] [Abstract][Full Text] [Related]
8. Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd LA; Mercier T; Ternon B; Cruchon S; Guignard N; Lahrichi S; Pesse B; Rochat B; Burger R; Lamoth F; Pagani JL; Eggimann P; Csajka C; Choong E; Buclin T; Widmer N; André P; Marchetti O
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122160. PubMed ID: 32891946
[TBL] [Abstract][Full Text] [Related]
9. Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.
Aardema H; Nannan Panday P; Wessels M; van Hateren K; Dieperink W; Kosterink JGW; Alffenaar JW; Zijlstra JG
Int J Antimicrob Agents; 2017 Jul; 50(1):68-73. PubMed ID: 28501674
[TBL] [Abstract][Full Text] [Related]
10. Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion.
Dhaese SAM; Colin P; Willems H; Heffernan A; Gadeyne B; Van Vooren S; Depuydt P; Hoste E; Stove V; Verstraete AG; Lipman J; Roberts JA; De Waele JJ
Int J Antimicrob Agents; 2019 Dec; 54(6):741-749. PubMed ID: 31479741
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
[TBL] [Abstract][Full Text] [Related]
12. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
[TBL] [Abstract][Full Text] [Related]
15. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course.
Carlier M; Carrette S; Stove V; Verstraete AG; De Waele JJ
Int J Antimicrob Agents; 2014 May; 43(5):470-3. PubMed ID: 24685990
[TBL] [Abstract][Full Text] [Related]
16. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
[TBL] [Abstract][Full Text] [Related]
17. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
Li Z; Chen Y; Li Q; Cao D; Shi W; Cao Y; Wu D; Zhu Y; Wang Y; Chen C
Eur J Clin Pharmacol; 2013 Jun; 69(6):1223-33. PubMed ID: 23354809
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
